2023
DOI: 10.1016/j.jbi.2023.104319
|View full text |Cite
|
Sign up to set email alerts
|

APLUS: A Python library for usefulness simulations of machine learning models in healthcare

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1
1

Relationship

3
4

Authors

Journals

citations
Cited by 15 publications
(12 citation statements)
references
References 60 publications
0
12
0
Order By: Relevance
“…APLUS is a novel framework that simulates care management workflows to assess the usefulness of ML models for deployment and integration 37 . It models nearly any workflow by defining workflows as sets of discrete states and transitions.…”
Section: Discussionmentioning
confidence: 99%
“…APLUS is a novel framework that simulates care management workflows to assess the usefulness of ML models for deployment and integration 37 . It models nearly any workflow by defining workflows as sets of discrete states and transitions.…”
Section: Discussionmentioning
confidence: 99%
“…In essence, we need to evolve our unit of examination from the model to the model plus the care workflow it drives. 3,8 The study by Clark and colleagues 1 does not venture this deep into the field, and the FDA is constrained in its ability to fully assess the risks and benefits of AI-and ML-enabled devices in context. Without full and accurate disclosures of how devices work, device adopters and monitors, too, are hamstringed in critical ways.…”
Section: + Related Articlementioning
confidence: 99%
“…To fully fathom the implications of the discrepancies that Clark and colleagues identify, it is necessary to examine the decisions that would be made (and the action that would be taken or withheld) based on the AI- and ML-enabled devices’ output. In essence, we need to evolve our unit of examination from the model to the model plus the care workflow it drives . The study by Clark and colleagues does not venture this deep into the field, and the FDA is constrained in its ability to fully assess the risks and benefits of AI- and ML-enabled devices in context.…”
mentioning
confidence: 99%
“…Overall, the most common countries for identified studies are the United States (44), followed by China (16), Europe (12), and Canada (6). The range of sample sizes reported in the studies varied from 41 to more than 4 million (Table 1).…”
Section: Baseline Featuresmentioning
confidence: 99%
“…To be useful in practice, models need to be validated and integrated into a clinical workflow, where capacity constraints and users ignoring alerts may limit the impact of even a perfectly performing model. 12 The purpose of this review is to collate the breadth of literature of ML in transfusion medicine, describing current trends and capturing key methodological approaches, adding to the recognized need for up-to-date discussion of the challenges and potential solutions to the prospective implementation of ML in transfusion medicine. 13 2 | METHODS…”
Section: Introductionmentioning
confidence: 99%